{{Drugbox
| IUPAC_name = 6-ethyl- 3-[(1-hydroxycyclopropyl)methyl]- 11,11-dimethyl- 1,2,3,4,5,6-hexahydro- 2,6-methano- 3-benzazocin-8- ol<br />or<br />2-(1-hydroxy- cyclopropylmethyl)- 5-ethyl- 9,9-dimethyl- 2'-hydroxy- 6,7-benzomorphan
| image = Bremazocine.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 75684-07-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 1223
| IUPHAR_ligand = 1603
| ChemSpiderID = 1186
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ISF76M2DBE
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1165792

<!--Chemical data-->
| C=20 | H=29 | N=1 | O=2 
| molecular_weight = 315.45 g/mol
| smiles = OC1(CC1)CN4[C@@H]3Cc2c(cc(O)cc2)[C@@](C3(C)C)(CC4)CC
}}

'''Bremazocine''' is a [[kappa-opioid receptor|κ-opioid receptor]] [[agonist]] related to [[pentazocine]]. It has [[potency (pharmacology)|potent]] and long-lasting [[analgesic]] and [[diuretic]] effects.<ref name="pmid16007240">{{cite journal |vauthors=Dortch-Carnes J, Potter DE |title=Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties |journal=CNS Drug Reviews |volume=11 |issue=2 |pages=195–212 |year=2005 |pmid=16007240 |doi= 10.1111/j.1527-3458.2005.tb00270.x|url=}}</ref> It has 200 times the activity of [[morphine]], but appears to have no addictive properties and does not depress breathing.<ref>{{cite book |last=Patrick |first=Graham |title=An Introduction to Medicinal Chemistry |edition=5th expanded |page=641 |publisher=Oxford University Press |date=2013 |isbn=0199697396 }}</ref>

== See also ==
* [[Benzomorphan]]

== References ==
{{reflist}}

{{Analgesics}}
{{Hallucinogens}}
{{Opioidergics}}

[[Category:Synthetic opioids]]
[[Category:Phenols]]
[[Category:Benzomorphans]]
[[Category:Kappa agonists]]
[[Category:Alcohols]]


{{nervous-system-drug-stub}}